Psoriatic Immune Response to Tildrakizumab

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT05390515
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Tildrakizumab Prefilled Syringe — DRUG
    IL-23 inhibitor

Study Details

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Key Dates

Start date
Sep 1, 2022
Status verified
Jun 2026
Primary completion
Sep 1, 2028
Completion
Sep 1, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Tildrakizumab treatment
    Biological/vaccine: tildrakizumab

Primary Outcome Measure

Change in Psoriasis Area and Severity Index (PASI) Score at baseline and 3 months of treatment [ Time Frame: Baseline, 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIP
University of California, San FranciscoSan FranciscoCalifornia94115

Find similar trials in San Francisco, CA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
University of California, San Francisco· San Francisco, CA

Related Studies